Citations 0
Letters to the Editor
August 2007


Author Affiliations

Copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2007

Arch Gen Psychiatry. 2007;64(8):978. doi:10.1001/archpsyc.64.8.978-a

The Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS)1 of the relative effectiveness of first (FGA)- and second (SGA)-generation antipsychotic treatments of schizophrenia reports negative findings, concluding that “there is no disadvantage across 1 year . . . in using FGAs. . . . ”1(p1079) In one commentary,2 Lieberman calls the findings of CUtLASS and the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study “virtually identical,” clearly referring to what he calls the “sobering”2(p1071) conclusion that “these studies found few differences in effectiveness between first-generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs). . . . ”2(p1069) In another commentary,3 Rosenheck writes that CUtLASS “echoes” CATIE, which “similarly, found no significant differences in time to all-cause discontinuation, the primary outcome. . . . ”2(p1075)

First Page Preview View Large
First page PDF preview
First page PDF preview